share_log

Bull Horn Holdings Corp. Combination Partner Coeptis Therapeutics Enters Into Exclusive Option Agreement With University Of Pittsburgh For Rights To CAR-T Technologies Designed To Target Multiple Cancer Indications, Including Hematologic And Solid Tumors

Bull Horn Holdings Corp. Combination Partner Coeptis Therapeutics Enters Into Exclusive Option Agreement With University Of Pittsburgh For Rights To CAR-T Technologies Designed To Target Multiple Cancer Indications, Including Hematologic And Solid Tumors

Bull Horn Holdings Corp. 合并合作伙伴Coeptis Therapeutics与匹兹堡大学签订独家期权协议,以获得旨在靶向多种癌症适应症(包括血液学和实体瘤)的CAR-T技术的权利
Benzinga Real-time News ·  2022/05/17 07:21
Option agreement comprises three technologies and associated patent portfolios
期权协议包括三项技术和相关的专利组合
Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms
该公告标志着Coeptis在本季度达成的第三份战略协议,旨在加强其产品组合并补充其创新的细胞疗法平台
WEXFORD, Pa., May 17, 2022 /PRNewswire/ -- Coeptis Therapeutics, Inc. (OTC:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced entry into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies that offer the potential to address a range of hematologic and solid tumors. Among the initial cancer indications under development...
宾夕法尼亚州韦克斯福德,2022 年 5 月 17 日 /PRNewswire/ — 开发癌症创新细胞疗法平台的生物制药公司 Coepti...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发